Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol Pamer, R.Ph. Carolyn McCloskey, M.D., M.P.H. March 4, 2005
Dec 29, 2015
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid
Division of Drug Risk Evaluation Office of Drug Safety
FDACarol Pamer, R.Ph.
Carolyn McCloskey, M.D., M.P.H.March 4, 2005
2
Outline
• Overview of Adverse Event Reporting System (AERS) and safety signal review
• Summary of pamidronate & zoledronic acid cases of osteonecrosis of the jaw (ONJ)
• Issues concerning review of AERS reports
• Considerations for future studies of ONJ
3
AERS (Adverse Event Reporting System)
• FDA has maintained a database of spontaneous reporting system case reports since 1969
• Number of modifications made, including coding dictionary, search interface, and expanded database capacity
4
Factors Affecting Reporting
• Nature of the adverse event• Type of drug product and indication• Length of time on market• Media attention• Extent and quality of manufacturer’s surveillance
system• Prescription or over-the-counter drug status• Reporting regulations
5
Evaluation of CasesGeneral Approach
• Adverse event occurrence in expected time• Absence of symptoms prior to exposure• Positive dechallenge or rechallenge• Consistent with pharmacological effects• Consistent with known effects in the class• Support from pre-clinical studies, clinical trials
• Absence of alternative explanations
6
Limitations of Spontaneous Reports• Passive surveillance
– Underreporting occurs and is variable from drug to drug and over time
• Reporting bias exists• Quality of the reports is variable and often
incomplete • Duplicate reporting occurs
• Can not reliably estimate incidence rates of events; numerator uncertain, denominator can only be projected
7
Best Applications of AERS
• Safety signal generation and descriptive case series
• Events that are linked to specific diagnoses
• Events with a serious outcome that rarely occur in an untreated population
• Events with a short-to-moderate latency period following exposure
8
Pamidronate & Zoledronic Acid
9
Spontaneous ReportsPamidronate & Zoledronic Acid
• Case series of postmarketing spontaneous reports
• Drugs: Pamidronate, Zoledronic acid
• Database search terms related to diagnosis of osteonecrosis/osteomyelitis
• Cut-off date: January 13, 2005
• Jaw involvement only, consistent w/ONJ
10
Spontaneous Reports of ONJ General Characteristics
Drug(s), as mentioned in reports (n = 654 reports) Percentage of TotalPamidronate only (n=136) 21 %Pamidronate and Zoledronic Acid, sequential use (n = 187) 28 %Zoledronic acid only (n = 318) 49 %Pamidronate, Zoledronic acid and/or hx otherbisphosphonate mentioned (n =13)
2 %
TOTAL 100%
11
Spontaneous Reports of ONJ (cont.) General Characteristics
Primary Indication(s) for use Percentage of TotalMultiple Myeloma (n=214) 33%--MM and hx of other cancer (n = 9) 1%Breast Cancer (n = 169) 26%--BC and hx of other cancer (n = 2) < 1%Prostate Cancer (n = 43) 6%--PC and hx of other cancer (n =2) < 1%Cancer, unspecified or other type (n =107) 16%Osteoporosis, osteopenia, “osteolysis” (n = 7) 1%Unknown or other (n = 101) 15%TOTAL 100%
12
Difficulties in Assessing Cases
• Increased reporting likely due to DHP letter, publications, presentations,
• Confounding factors present in many
• Assessment of dechallenge, rechallenge confounded
• Determining time to onset of event
13
Confounding Factors
• Most reports listed one or more of the following: – Drugs : corticosteroids, other bisphosphonates,
thalidomide, cancer chemotherapy– Procedures: tooth extractions– Medical conditions: cancer
• Missing information in others
14
Limitations of Dechallenge Assessment
• ONJ did not quickly resolve, regardless of therapies and drug dechallenge
• Most patients had continuing symptoms as of last follow-up obtained
• Multiple therapeutic interventions received by most patients
• Persistence of bisphosphonates in bone
15
Determining Time to Onset
• Many patients developed symptoms after dental procedure (tooth extraction) w/lesion that did not heal
• Case series only included diagnosed ONJ, not symptoms alone (e.g., jaw pain, tooth loss)
• In many cases, information on early symptoms was missing
16
Epidemiological Perspective
17
Challenges of Studying ONJ
• ONJ rare event– Difficult to get background rates in general
population; difficult to monitor trends
• Difficulty in identifying cases with ONJ in databases – No specific ICD-9 code
• Difficulty obtaining data on drug exposure• Lack of suitable control/comparison groups
18
Potential Study Data Sources
• Oncology Clinics
– IV Bisphosphonate-Exposed Population
• Dentists & Oral Surgeons– Cases of ONJ
• Registry of all cases identified in different settings
19
Considerations for Future Studies
• Limited utility of available data– Pharmacoepidemiological or postmarketing
surveillance data
• Randomized, controlled trial data may be superior to data from these sources
• Use of registry to collect cases might be explored
20
Conclusion
• Cases of ONJ reported in association with these drugs represent a highly plausible signal– Site specificity
– Number of reports submitted to AERS
– Temporal association
– Serious outcome
• To identify contributing risk factors other studies are necessary
21
Acknowledgements
• Mark Avigan, M.D., C.M.
• Jennie Chang, Pharm.D.
• Lanh Green, Pharm.D., M.P.H.
• Mary Willy, Ph.D.